Rituximab in ANCA-Associated Vasculitis

被引：41
|
作者：
Hassan, Romina I. [1 ]
Gaffo, Angelo L. [2 ,3 ]
机构：
[1] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina
[2] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA
[3] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2017年 / 19卷 / 02期
关键词：
Rituximab; Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith polyangiitis (EGPA); WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE; INDUCTION; REMISSION; THERAPY; MAINTENANCE; MANAGEMENT; RELAPSES;
D O I：
10.1007/s11926-017-0632-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA). Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS
    Mukhtyar, Chetan
    RHEUMATOLOGY, 2013, 52 : 5 - 6
  • [2] Rituximab in ANCA-Associated Vasculitis
    Romina I. Hassan
    Angelo L. Gaffo
    Current Rheumatology Reports, 2017, 19
  • [3] Rituximab: effective in ANCA-associated vasculitis?
    Ulf Schönermarck
    Kirsten de Groot
    Nature Reviews Nephrology, 2011, 7 : 6 - 8
  • [4] Rituximab: effective in ANCA-associated vasculitis?
    Schoenermarck, Ulf
    de Groot, Kirsten
    NATURE REVIEWS NEPHROLOGY, 2011, 7 (01) : 6 - 8
  • [5] Rituximab in ANCA-associated vasculitis: a revolution?
    Tervaert, Jan Willem Cohen
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (10) : 3077 - 3079
  • [6] Rituximab to treat ANCA-associated vasculitis
    Guillevin, L.
    Mahr, A.
    REVUE DE MEDECINE INTERNE, 2011, 32 (10): : 591 - 593
  • [7] Rituximab treatment of ANCA-associated vasculitis
    Raffray, Loic
    Guillevin, Loic
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (08) : 899 - 910
  • [8] Rituximab versus azathioprine for ANCA-associated vasculitis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2023, 5 (05): : e252 - e252
  • [9] Rituximab or Cyclophosphamide in ANCA-Associated Renal Vasculitis
    Hebert, Lee A.
    Ardoin, Stacy
    Shim, Rosemarie L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (21): : 2072 - 2073
  • [10] Rituximab maintenance therapy in ANCA-associated vasculitis
    Lorenz, Judith
    AKTUELLE RHEUMATOLOGIE, 2024, 49 (05) : 281 - 281
12345